Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion

Leukemia

Volumn 22, Issue 6, 2008, Pages 1273-1274

  Tamai, H ^a   Shioi, Y ^a   Yamaguchi, H ^a   Okabe, M ^a   Wakita, S ^a   Mizuki, T ^a   Nakayama, K ^a   Inokuchi, K ^a   Tajika, K ^a   Dan, K ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MESSENGER RNA; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN AF6;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 6; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA TRANSCRIPTION; SEPSIS; VEIN OCCLUSION; WHOLE BODY RADIATION;

EID: 45149119378     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405029     Document Type: Article

References (5)

1. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia 2007; 21: 66-71.
2. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology 2006 Education program book. American Society of Hematology: Washington, DC, 2006, 169-177.
3. Garrido SM, Bryant E, Appelbaum FR. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11 q23 abnormalities. Leuk Res 2000; 24: 481-486.
4. Larson RA, Sivers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H et al. Final report on the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33 positive acute myeloid leukemia in first recurrence. Cancer 2001; 104: 1442-1452.
5. Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76-82.